Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FPC.0b013e32834b6918PMID 21946896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

  2010cited by this paper
• NAD(P)H Quinone Oxidoreductase Protects TAp63γ from Proteasomal Degradation and Regulates TAp63γ-Dependent Growth Arrest

  2010cited by this paper
• CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

  2010cited by this paper
• Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.

  2009cited by this paper
• Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53.

  2009cited by this paper
• Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

  2009cited by this paper
• Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2

  2009cited by this paper
• Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.

  2009cited by this paper
• NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

  2008cited by this paper
• Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease.

  2008cited by this paper
• Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer

  2008cited by this paper
• NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33ING1b

  2008cited by this paper
• NQO1*2 polymorphism and response to treatment in patients with multiple myeloma.

  2007cited by this paper
• NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53.

  2007cited by this paper
• The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia.

  2007cited by this paper
• NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

  2007cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• NRH:quinone reductase 2: an enzyme of surprises and mysteries.

  2005cited by this paper
• A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73.

  2005cited by this paper
• Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations

  2004cited by this paper
• Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy

  2002cited by this paper
• Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.

  2002cited by this paper
• Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia.

  2002cited by this paper
• NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese

  2002cited by this paper
• Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1.

  2001cited by this paper
• Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.

  1999cited by this paper
• Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

  1997cited by this paper
• Establishment by Adriamycin Exposure of Multidrug‐resistant Rat Ascites Hepatoma AH130 Cells Showing Low DT‐diaphorase Activity and High Cross Resistance to Mitomycins

  1997cited by this paper
• Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.

  1997cited by this paper
• Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.

  1995cited by this paper
• DT‐diaphorase as a determinant of sensitivity to adriamycin in non‐small‐cell lung‐cancer cell lines

  1994cited by this paper
• Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.

  1994cited by this paper
• NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues

  1993cited by this paper
• The enzymology of doxorubicin quinone reduction in tumour tissue.

  1992cited by this paper
• Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.

  1990cited by this paper
• Adriamycin and DT-diaphorase.

  1986cited by this paper
• DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation.

  1982cited by this paper

• Impact of NQO1, GSTM1 and GSTT1 genetic variants on susceptibility and relapse in childhood acute lymphoblastic leukemia.

  2026cites this paper
• Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients

  2024cites this paper
• Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future

  2024cites this paper
• Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review.

  2023cites this paper
• Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy

  2022cites this paper
• Six-gene Signature Based on Metabolism Is Closely Related to the Prognosis and Immune Infiltration of Patients With Sepsis

  2021cites this paper
• Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

  2021cites this paper
• Single nucleotide polymorphisms as the efficient prognostic markers in breast cancer.

  2021cites this paper
• Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women

  2021cites this paper
• Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives.

  2021cites this paper
• MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

  2020cites this paper
• Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial

  2020cites this paper
• Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array

  2018cites this paper
• The Prevalence of Ultrarapid Metabolizers of Codeine in a Diverse Urban Population

  2018cites this paper
• Title : NAD ( P ) H dehydrogenase , quinone 1 ( NQO 1 ) protects melanin-producing cells from cytotoxicity of rhododendrol

  2018cites this paper
• Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer

  2018cites this paper
• The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2)

  2017cites this paper
• Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines.

  2017cites this paper
• Azoreductases in drug metabolism

  2017cites this paper
• Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

  2017cites this paper
• microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview

  2017cites this paper
• Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

  2017cites this paper
• Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

  2017cites this paper
• NAD(P)H dehydrogenase, quinone 1 (NQO1), protects melanin‐producing cells from cytotoxicity of rhododendrol

  2016cites this paper
• Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients

  2016cites this paper
• Pharmacogenetic Predictors of Response.

  2016cites this paper
• Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients

  2015influential citation
• The potential role of the oxidoreductase, NQO2, in breast cancer

  2015influential citation
• Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

  2015cites this paper
• FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1.

  2014cites this paper
• The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties

  2014cites this paper
• Clinical implications of high NQO1 expression in breast cancers

  2014cites this paper
• Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil

  2014cites this paper
• Resistance to Anthracyclines and Taxanes in Breast Cancer

  2013cites this paper
• Overview of High Throughput Sequencing Technologies to Elucidate Molecular Pathways in Cardiovascular Diseases

  2013cites this paper
• Detection of single nucleotide polymorphisms by PCR conformation-difference gel electrophoresis

  2012cites this paper
• Institutional profile: pharmacogenomics research at Newcastle University.

  2012cites this paper
• NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

  2012cites this paper
• Low expression of NQO1 predicts pathological complete response to neoadjuvant chemotherapy in breast cancer patients treated with TAC regimen.

  2012cites this paper